MatthewJamesButlerMD

Hematology • San Antonio, TX

Hematologic Oncology

Assistant Professor

Join to view full profile

Dr. Butler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Butler's full profile

Already have an account?

Office
7979 Wurzbach Rd
San Antonio, TX 78229
Phone+1 210-450-1143

Fax+1 210-450-0407

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2015 - 2018
Geisinger Health System (Danville)Residency, Internal Medicine, 2012 - 2015
Saba University School of MedicineClass of 2011

Certifications & Licensure

TX State Medical License 2018 - 2026
DE State Medical License 2014 - 2019
PA State Medical License 2011 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned.
Chase V West, Matthew J Butler, Supreet Kaur, Elizabeth Bowhay-Carnes, Anand B Karnad
JCO Oncology Practice. 2024-01-01
90 citations
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
Diana Merino Vega, Laura M. Yee, Lisa M. McShane, Paul M. Williams, Li Chen
Annals of Oncology. 2021-10-01
4 citations
Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma
Srikanth R. Polusani, Valerie Cortez, Javier Esparza, Huynh Nga Nguyen, Hongxin Fan
International Journal of Cancer. 2021-01-31

Abstracts/Posters

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
Matthew James Butler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

KHN Morning BriefingApril 18th, 2022
'Step Closer to a Safer Way of Stopping Kidney Failure and Need for Dialysis in Diabetics'January 20th, 1970